Bloodless Lung Transplantation in Jehovah's Witnesses: Impact on Perioperative Parameters and Outcome Compared With a Matched Control Group

被引:11
作者
Partovi, S. [1 ]
Bruckner, B. A. [1 ]
Staub, D. [2 ]
Ortiz, G. [1 ]
Scheinin, S. A. [1 ]
Seethamraju, H. [1 ]
Loebe, M. [1 ]
机构
[1] Methodist Hosp, DeBakey Heart & Vasc Ctr, Dept Cardiovasc Surg, Houston, TX 77030 USA
[2] Univ Basel Hosp, Dept Angiol, CH-4031 Basel, Switzerland
关键词
RECOMBINANT-HUMAN-ERYTHROPOIETIN; CARDIOPULMONARY BYPASS; LIVER-TRANSPLANTATION; HEMOLYTIC-ANEMIA; IRON-METABOLISM; TRANSFUSION; SURGERY; STRATEGIES; EXPERIENCE; SALVAGE;
D O I
10.1016/j.transproceed.2012.06.057
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Jehovah's Witnesses (JW) refuse to receive blood products due to their religious beliefs. Bloodless transplantation programs have made the successful transplantation of solid organs like heart, liver, kidney, and pancreas in JW feasible. In this study we present the third and fourth case of a successful bloodless lung transplantation and analyze perioperative parameters and outcome with a strictly selected matched control group (CG). Methods. Two JW patients suffering from idiopathic pulmonary fibrosis had single lung transplantation in the transfusion-free program. Ten of 113 patients (8.8%) undergoing lung transplantation fulfilled the matching criteria and served as CO. Perioperative parameters including blood loss and transfusions were collected from the charts. Regarding outcome parameters arterial blood gas, lung function testing, length of stay, and survival were analyzed. Results. Concerning perioperative parameters no significant differences could be found between both groups except for the creatinine level, which was significantly lower in the JW group on postoperative day 0 (P = .037), and the hemoglobin and hematocrit levels, which were significantly higher in the JW group on postoperative day 3 (P = .032 and P = .041, respectively). The analysis of the outcome parameters revealed significantly higher postoperative lung functional testing values forced expiratory volume after 1 second (FEV1) and forced vital capacity (FVC) in the JW group compared with the CO (P = .037 and P = .036, respectively). Conclusion. Bloodless lung transplantation is feasible in carefully selected JW recipients. Comparing JW to CG, no statistically significant difference in the perioperative course and a trend towards a favorable postoperative lung function outcome were detected.
引用
收藏
页码:335 / 341
页数:7
相关论文
共 47 条
[1]  
Adamson J, 1996, SEMIN HEMATOL, V33, P5
[2]   Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report [J].
Agrawal, YP ;
Freedman, M ;
Szczepiorkowski, ZM .
TRANSFUSION, 2005, 45 (11) :1735-1738
[3]   Cell salvage as part of a blood conservation strategy in anaesthesia [J].
Ashworth, A. ;
Klein, A. A. .
BRITISH JOURNAL OF ANAESTHESIA, 2010, 105 (04) :401-416
[4]   Meeting the clinical challenge of care for Jehovah's Witnesses [J].
Bodnaruk, ZM ;
Wong, CJ ;
Thomas, MJ .
TRANSFUSION MEDICINE REVIEWS, 2004, 18 (02) :105-116
[5]   Kidney and pancreas transplants in Jehovah's witnesses: Ethical and practical implications [J].
Boggi, U ;
Vistoli, F ;
Del Chiaro, M ;
Croce, C ;
Signori, S ;
Marchetti, P ;
Del Prato, S ;
Rizzo, G ;
Mosca, F .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (03) :601-602
[6]   Pancreas transplantation from marginal donors [J].
Boggi, U ;
Del Chiaro, M ;
Vistoli, F ;
Signori, S ;
Bartolo, TV ;
Gremmo, F ;
Marchetti, P ;
Coppelli, A ;
Rizzo, G ;
Mosca, F .
TRANSPLANTATION PROCEEDINGS, 2004, 36 (03) :566-568
[7]  
BURNETT CM, 1990, ARCH SURG-CHICAGO, V125, P1430
[8]   Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion [J].
Carson, JL ;
Noveck, H ;
Berlin, JA ;
Gould, SA .
TRANSFUSION, 2002, 42 (07) :812-818
[9]   Lung transplantation in a Jehovah's Witness [J].
Conte, JV ;
Orens, JB .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1999, 18 (08) :796-800
[10]  
CORNO A F, 1986, Journal of Heart Transplantation, V5, P175